An update from Icecure Medical ( (ICCM) ) is now available.
IceCure Medical reported a significant 42% growth in sales of its ProSense® Cryoablation System in North America for 2024, reflecting increased adoption of its minimally invasive tumor treatment technology. The company is awaiting an FDA decision on marketing authorization for ProSense® in early-stage low-risk breast cancer, which could further enhance its market position. Financial results for 2024 showed an increase in total revenue and gross profit, driven by higher product sales, despite a slight increase in net loss. The company continues to expand globally, with expectations for regulatory approvals in Japan and Israel, and ongoing publication of positive study results.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, specializes in developing and marketing advanced cryoablation therapy systems using liquid nitrogen to treat tumors, both benign and cancerous. The company’s primary focus is on breast, kidney, bone, and lung cancer. Their minimally invasive technology offers a safe and effective alternative to traditional surgical tumor removal.
YTD Price Performance: -7.32%
Average Trading Volume: 378,812
Technical Sentiment Signal: Sell
Current Market Cap: $64.49M
For detailed information about ICCM stock, go to TipRanks’ Stock Analysis page.